Long Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Long Xie has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
David A. Wolk
University of Pennsylvania, Philadelphia, PA USA
19 shared publicationsSandhitsu R. Das
University of Pennsylvania, Philadelphia, PA USA
15 shared publications- Paul A. Yushkevich
Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
12 shared publications Paul A. Yushkevich
University of Pennsylvania, Philadelphia, PA USA
11 shared publicationsLaura E. M. Wisse
Department of Diagnostic Radiology Lund University Lund Sweden
8 shared publicationsRanjit Ittyerah
Department of Radiology University of Pennsylvania Philadelphia Pennsylvania USA
8 shared publications
Latest Publications
- Open Access
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S7) , e108066
Artificial Intelligence Monitoring of ARIA‐H in Real‐World Patients Receiving Anti‐Amyloid Therapy
Background: Effective monitoring of amyloid‐related imaging abnormalities (ARIA) is a safety requirement with anti‐amyloid treatments for Alzheimer’s disease (AD). However, variability in clinical settings, limited availability of expert neuroradiologists, and the substantial volume of medical images required for ARIA monitoring pose significant challenges, reducing accessibility and increasing healthcare costs. Our previously developed artificial intelligence (AI)‐based ARIA detection tool (Figure 1) has the potential to address these challenges but has not been evaluated with “real‐world” AD patient data. This study aims to assess the effectiveness of our ARIA tool in detecting ARIA‐H events in patients undergoing anti‐amyloid therapy. Methods: We included longitudinal susceptibility‐weighted‐imaging (SWI) MRI scans of 49 patients receiving anti‐amyloid therapy at the University of Pennsylvania (Table 1). Experienced radiologist identified ARIA‐H events from the 124 monitoring timepoints by detecting new micro‐hemorrhages or superficial siderosis, serving as the ground truth. Our AI tool, based on a foundation model additionally trained on SWI scans with micro‐hemorrhages due to non‐anti‐amyloid therapy conditions, was applied to each SWI scan to count micro‐hemorrhages. If a monitoring timepoint showed more micro‐hemorrhages than the previous timepoint or the baseline timepoint, it was considered a positive AI‐detected ARIA‐H event. The AI system’s performance was measured by comparing the AI detections to the radiologist‐rated ground truth using negative predictive value (NPV), positive predictive value (PPV), sensitivity and specificity. Results: 22.4% of patients (11 out of 49) developed ARIA‐H, consistent with the ARIA‐H rate observed in clinical trials. As shown in the confusion table (Table 2), out of 68 negative AI‐detected ARIA‐H events, 67 were true negatives, resulting in a high NPV of 98.5%. In addition, the AI system achieved 93.3% sensitivity in detecting ground truth positive ARIA‐H events (14 out of 15). The PPV and specificity were 25% and 61.5% respectively. Conclusions: The findings demonstrate that the proposed AI system can be used to identify low‐risk monitoring timepoints for ARIA‐H. This suggests potential for reducing radiology workload and serving as a screener for radiology evaluation, thereby enhancing the efficiency, cost‐effectiveness, consistency, and accessibility of ARIA‐H monitoring. Future work will incorporate longitudinal ARIA‐H training data to improve the PPV and specificity.
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S7) , e108066
Open AccessArtificial Intelligence Monitoring of ARIA‐H in Real‐World Patients Receiving Anti‐Amyloid Therapy
Background: Effective monitoring of amyloid‐related imaging abnormalities (ARIA) is a safety requirement with anti‐amyloid treatments for Alzheimer’s disease (AD). However, variability in clinical settings, limited availability of expert neuroradiologists, and the substantial volume of medical images required for ARIA monitoring pose significant challenges, reducing accessibility and increasing healthcare costs. Our previously developed artificial intelligence (AI)‐based ARIA detection tool (Figure 1) has the potential to address these challenges but has not been evaluated with “real‐world” AD patient data. This study aims to assess the effectiveness of our ARIA tool in detecting ARIA‐H events in patients undergoing anti‐amyloid therapy. Methods: We included longitudinal susceptibility‐weighted‐imaging (SWI) MRI scans of 49 patients receiving anti‐amyloid therapy at the University of Pennsylvania (Table 1). Experienced radiologist identified ARIA‐H events from the 124 monitoring timepoints by detecting new micro‐hemorrhages or superficial siderosis, serving as the ground truth. Our AI tool, based on a foundation model additionally trained on SWI scans with micro‐hemorrhages due to non‐anti‐amyloid therapy conditions, was applied to each SWI scan to count micro‐hemorrhages. If a monitoring timepoint showed more micro‐hemorrhages than the previous timepoint or the baseline timepoint, it was considered a positive AI‐detected ARIA‐H event. The AI system’s performance was measured by comparing the AI detections to the radiologist‐rated ground truth using negative predictive value (NPV), positive predictive value (PPV), sensitivity and specificity. Results: 22.4% of patients (11 out of 49) developed ARIA‐H, consistent with the ARIA‐H rate observed in clinical trials. As shown in the confusion table (Table 2), out of 68 negative AI‐detected ARIA‐H events, 67 were true negatives, resulting in a high NPV of 98.5%. In addition, the AI system achieved 93.3% sensitivity in detecting ground truth positive ARIA‐H events (14 out of 15). The PPV and specificity were 25% and 61.5% respectively. Conclusions: The findings demonstrate that the proposed AI system can be used to identify low‐risk monitoring timepoints for ARIA‐H. This suggests potential for reducing radiology workload and serving as a screener for radiology evaluation, thereby enhancing the efficiency, cost‐effectiveness, consistency, and accessibility of ARIA‐H monitoring. Future work will incorporate longitudinal ARIA‐H training data to improve the PPV and specificity.
- Open Access
- 7 October 2025
- Published by Wiley in Hippocampus
- Vol. 35 (6) , e70036
Automatic Segmentation of Medial Temporal Lobe Subregions in Multi‐Scanner, Multi‐Modality Magnetic Resonance Imaging of Variable Quality
Volumetry of subregions in the medial temporal lobe (MTL) computed from automatic segmentation in MRI can track neurodegeneration in Alzheimer's disease. However, poor quality MR images can lead to unreliable segmentation of MTL subregions. Considering that different MRI contrast mechanisms and field strengths (jointly referred to as “modalities” here) offer distinct advantages in imaging different parts of the MTL, we developed a multi‐modality segmentation model using both 7T and 3T structural MRI to obtain robust segmentation in poor‐quality images. MRI modalities including 3T T1‐weighted, 3T T2‐weighted, 7T T1‐weighted and 7T T2‐weighted (7T‐T2w) of 197 participants were collected from a longitudinal aging study at the Penn Alzheimer's Disease Research Center. Among them, 7T‐T2w was used as the primary modality, and all other modalities were rigidly registered to the 7T‐T2w. A model derived from nnU‐Net took these registered modalities as input and outputted subregion segmentation in 7T‐T2w space. 7T‐T2w images most of which had high quality from 25 selected training participants were manually segmented to train the multi‐modality model. Modality augmentation, which randomly replaced certain modalities with Gaussian noise, was applied during training to guide the model to extract information from all modalities. The multi‐modality model delivered good performance regardless of 7T‐T2w quality, while the single‐modality model under‐segmented subregions in poor‐quality images. The multi‐modality model generally demonstrated stronger discrimination of A + MCI versus A‐CU. Intra‐class correlation and Bland–Altman plots demonstrate that the multi‐modality model had higher longitudinal segmentation consistency in all subregions while the single‐modality model had low consistency in poor‐quality images. The multi‐modality MRI segmentation model provides an improved biomarker for neurodegeneration in the MTL that is robust to image quality. It also provides a framework for other studies which may benefit from multimodal imaging.
- 7 October 2025
- Published by Wiley in Hippocampus
- Vol. 35 (6) , e70036
Open AccessAutomatic Segmentation of Medial Temporal Lobe Subregions in Multi‐Scanner, Multi‐Modality Magnetic Resonance Imaging of Variable Quality
Volumetry of subregions in the medial temporal lobe (MTL) computed from automatic segmentation in MRI can track neurodegeneration in Alzheimer's disease. However, poor quality MR images can lead to unreliable segmentation of MTL subregions. Considering that different MRI contrast mechanisms and field strengths (jointly referred to as “modalities” here) offer distinct advantages in imaging different parts of the MTL, we developed a multi‐modality segmentation model using both 7T and 3T structural MRI to obtain robust segmentation in poor‐quality images. MRI modalities including 3T T1‐weighted, 3T T2‐weighted, 7T T1‐weighted and 7T T2‐weighted (7T‐T2w) of 197 participants were collected from a longitudinal aging study at the Penn Alzheimer's Disease Research Center. Among them, 7T‐T2w was used as the primary modality, and all other modalities were rigidly registered to the 7T‐T2w. A model derived from nnU‐Net took these registered modalities as input and outputted subregion segmentation in 7T‐T2w space. 7T‐T2w images most of which had high quality from 25 selected training participants were manually segmented to train the multi‐modality model. Modality augmentation, which randomly replaced certain modalities with Gaussian noise, was applied during training to guide the model to extract information from all modalities. The multi‐modality model delivered good performance regardless of 7T‐T2w quality, while the single‐modality model under‐segmented subregions in poor‐quality images. The multi‐modality model generally demonstrated stronger discrimination of A + MCI versus A‐CU. Intra‐class correlation and Bland–Altman plots demonstrate that the multi‐modality model had higher longitudinal segmentation consistency in all subregions while the single‐modality model had low consistency in poor‐quality images. The multi‐modality MRI segmentation model provides an improved biomarker for neurodegeneration in the MTL that is robust to image quality. It also provides a framework for other studies which may benefit from multimodal imaging.
- Open Access
- 30 July 2025
- Published by Wiley in Hippocampus
- Vol. 35 (5) , e70027
Developing an Anatomically Valid Segmentation Protocol for Anterior Regions of the Medial Temporal Lobe for Neurodegenerative Diseases
The anterior portion of the medial temporal lobe (MTL) is one of the first regions targeted by pathology in sporadic Alzheimer's disease (AD) and limbic‐predominant age‐related TDP‐43 encephalopathy (LATE) indicating a potential for metrics from this region to serve as imaging biomarkers. Leveraging a unique post‐mortem dataset of histology and magnetic resonance imaging (MRI) scans, we aimed to (1) develop an anatomically valid segmentation protocol for anterior entorhinal cortex (ERC), Brodmann area (BA) 35, and BA36 for in vivo 3 T MRI and (2) incorporate this protocol in an automated approach. We included 20 cases (61–97 years old, 50% females) with and without neurodegenerative diseases (11 vs. 9 cases) to ensure generalizability of the developed protocol. Digitized MTL Nissl‐stained coronal histology sections from these cases were annotated and registered to same‐subject post‐mortem MRI. The protocol was developed by determining the location of histological borders of the MTL cortices in relation to anatomical landmarks. Subsequently, the protocol was applied to 15 cases twice, with a 2‐week interval, to assess intra‐rater reliability with the Dice Similarity Index (DSI). Thereafter, it was implemented in our in‐house Automatic Segmentation of Hippocampal Subfields (ASHS)‐T1 approach and evaluated with DSIs. The anterior histological border distances of ERC, BA35 and BA36 were evaluated with respect to various anatomical landmarks, and the distance relative to the beginning of the hippocampus was chosen. To formulate segmentation rules, we examined the histological sections for the location of borders in relationship to anatomical landmarks in the coronal sections. The DSI for the anterior MTL cortices for the intra‐rater reliability was 0.85–0.88, and for the ASHS‐T1 against the manual segmentation, it was 0.62–0.65. We developed a reliable segmentation protocol and incorporated it in an automated approach. Given the vulnerability of the anterior MTL cortices to tau deposition in AD and LATE, the updated approach is expected to improve imaging biomarkers for these diseases.
- 30 July 2025
- Published by Wiley in Hippocampus
- Vol. 35 (5) , e70027
Open AccessDeveloping an Anatomically Valid Segmentation Protocol for Anterior Regions of the Medial Temporal Lobe for Neurodegenerative Diseases
The anterior portion of the medial temporal lobe (MTL) is one of the first regions targeted by pathology in sporadic Alzheimer's disease (AD) and limbic‐predominant age‐related TDP‐43 encephalopathy (LATE) indicating a potential for metrics from this region to serve as imaging biomarkers. Leveraging a unique post‐mortem dataset of histology and magnetic resonance imaging (MRI) scans, we aimed to (1) develop an anatomically valid segmentation protocol for anterior entorhinal cortex (ERC), Brodmann area (BA) 35, and BA36 for in vivo 3 T MRI and (2) incorporate this protocol in an automated approach. We included 20 cases (61–97 years old, 50% females) with and without neurodegenerative diseases (11 vs. 9 cases) to ensure generalizability of the developed protocol. Digitized MTL Nissl‐stained coronal histology sections from these cases were annotated and registered to same‐subject post‐mortem MRI. The protocol was developed by determining the location of histological borders of the MTL cortices in relation to anatomical landmarks. Subsequently, the protocol was applied to 15 cases twice, with a 2‐week interval, to assess intra‐rater reliability with the Dice Similarity Index (DSI). Thereafter, it was implemented in our in‐house Automatic Segmentation of Hippocampal Subfields (ASHS)‐T1 approach and evaluated with DSIs. The anterior histological border distances of ERC, BA35 and BA36 were evaluated with respect to various anatomical landmarks, and the distance relative to the beginning of the hippocampus was chosen. To formulate segmentation rules, we examined the histological sections for the location of borders in relationship to anatomical landmarks in the coronal sections. The DSI for the anterior MTL cortices for the intra‐rater reliability was 0.85–0.88, and for the ASHS‐T1 against the manual segmentation, it was 0.62–0.65. We developed a reliable segmentation protocol and incorporated it in an automated approach. Given the vulnerability of the anterior MTL cortices to tau deposition in AD and LATE, the updated approach is expected to improve imaging biomarkers for these diseases.
- Open Access
- 25 July 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (7) , e70511
Tau, atrophy, and domain‐specific cognitive impairment in typical Alzheimer's disease
INTRODUCTION: A granular understanding of the mechanisms linking tau pathology to cognitive decline in Alzheimer's disease is crucial. We investigate mediating effects of medial temporal lobe (MTL) and neocortical neurodegeneration on tau‐induced domain‐specific cognitive impairment in amyloid‐beta (Aβ) positive cognitively normal and impaired adults. METHODS: We assessed magnetic resonance imaging–derived MTL and neocortical volume/thickness and 18 F‐Flortaucipir positron emission tomography in 319 Aβ‐positive individuals. Cognitive functions across six domains were isolated by adjusting for other cognitive measures. RESULTS: MTL tau correlated with memory subdomains, neocortical tau with executive function, and both with semantic fluency. Specific structural measures partially mediated these tau–cognition associations: Brodmann area 35 mediated tau–immediate and tau–delayed recall, posterior hippocampus tau–recognition, and inferior temporal cortex tau–semantic fluency associations. DISCUSSION: Our findings provide a nuanced understanding of region‐specific macrostructural atrophy as one pathway of tau‐induced cognitive changes, aligning with known tau spread patterns. Additionally, isolating cognitive functions is a promising approach for future research. Highlights: Medial temporal lobe tau was related to memory domains; neocortical tau to executive function. Both tau positron emission tomography measures were associated with semantic fluency. Specific regional atrophy partially mediated tau‐induced cognitive changes. Other mechanistic links between tau and cognitive subdomains require investigation. Isolated cognitive domains should be explored as future avenues of research.
- 25 July 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (7) , e70511
Open AccessTau, atrophy, and domain‐specific cognitive impairment in typical Alzheimer's disease
INTRODUCTION: A granular understanding of the mechanisms linking tau pathology to cognitive decline in Alzheimer's disease is crucial. We investigate mediating effects of medial temporal lobe (MTL) and neocortical neurodegeneration on tau‐induced domain‐specific cognitive impairment in amyloid‐beta (Aβ) positive cognitively normal and impaired adults. METHODS: We assessed magnetic resonance imaging–derived MTL and neocortical volume/thickness and 18 F‐Flortaucipir positron emission tomography in 319 Aβ‐positive individuals. Cognitive functions across six domains were isolated by adjusting for other cognitive measures. RESULTS: MTL tau correlated with memory subdomains, neocortical tau with executive function, and both with semantic fluency. Specific structural measures partially mediated these tau–cognition associations: Brodmann area 35 mediated tau–immediate and tau–delayed recall, posterior hippocampus tau–recognition, and inferior temporal cortex tau–semantic fluency associations. DISCUSSION: Our findings provide a nuanced understanding of region‐specific macrostructural atrophy as one pathway of tau‐induced cognitive changes, aligning with known tau spread patterns. Additionally, isolating cognitive functions is a promising approach for future research. Highlights: Medial temporal lobe tau was related to memory domains; neocortical tau to executive function. Both tau positron emission tomography measures were associated with semantic fluency. Specific regional atrophy partially mediated tau‐induced cognitive changes. Other mechanistic links between tau and cognitive subdomains require investigation. Isolated cognitive domains should be explored as future avenues of research.
- Open Access
- 27 January 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (2)
A multi‐cohort study of longitudinal and cross‐sectional Alzheimer's disease biomarkers in cognitively unimpaired older adults
INTRODUCTION: The generalizability of neuroimaging and cognitive biomarkers in their sensitivity to detect preclinical Alzheimer's disease (AD) and power to predict progression in large, multisite cohorts remains unclear. METHOD: Longitudinal demographics, T1‐weighted magnetic resonance imaging (MRI), and cognitive scores of 3036 cognitively unimpaired (CU) older adults (amyloid beta [Aβ]‐negative/positive [A–/A+]: 1270/1558) were included. Cross‐sectional and longitudinal cognition and medial temporal lobe (MTL) structural measures were extracted. Cross‐sectional MTL tau burden (T) was computed from tau positron emission tomography ( N = 1095). RESULTS: We found cross‐sectional tau and longitudinal structural biomarkers best separated A+ CU from A– CU. A–T+ CU had significantly faster neurodegeneration rate compared to A–T– CU. MTL tau was significantly correlated with MRI and cognitive biomarkers regardless of Aβ status. MTL tau, MRI, and cognition provided complementary information about disease progression. DISCUSSION: This large multisite study replicates prior findings in CU older adults, supporting the utility of neuroimaging and cognitive biomarkers in preclinical AD clinical trials and normal aging studies. Highlights: We investigated neuroimaging and cognitive biomarkers in 3036 cognitively unimpaired (CU) participants. Medial temporal lobe (MTL) tau and longitudinal MTL atrophy best separate amyloid beta positive (A+) CU from amyloid beta negative (A–) CU. A– tau positive (T+) CU had a significantly faster neurodegeneration rate compared to A–T– CU. MTL tau correlated with structural magnetic resonance imaging (MRI) and cognition regardless of amyloid beta status. Combined baseline MTL tau, MRI, and cognition best predict Alzheimer's disease progression.
- 27 January 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (2)
Open AccessA multi‐cohort study of longitudinal and cross‐sectional Alzheimer's disease biomarkers in cognitively unimpaired older adults
INTRODUCTION: The generalizability of neuroimaging and cognitive biomarkers in their sensitivity to detect preclinical Alzheimer's disease (AD) and power to predict progression in large, multisite cohorts remains unclear. METHOD: Longitudinal demographics, T1‐weighted magnetic resonance imaging (MRI), and cognitive scores of 3036 cognitively unimpaired (CU) older adults (amyloid beta [Aβ]‐negative/positive [A–/A+]: 1270/1558) were included. Cross‐sectional and longitudinal cognition and medial temporal lobe (MTL) structural measures were extracted. Cross‐sectional MTL tau burden (T) was computed from tau positron emission tomography ( N = 1095). RESULTS: We found cross‐sectional tau and longitudinal structural biomarkers best separated A+ CU from A– CU. A–T+ CU had significantly faster neurodegeneration rate compared to A–T– CU. MTL tau was significantly correlated with MRI and cognitive biomarkers regardless of Aβ status. MTL tau, MRI, and cognition provided complementary information about disease progression. DISCUSSION: This large multisite study replicates prior findings in CU older adults, supporting the utility of neuroimaging and cognitive biomarkers in preclinical AD clinical trials and normal aging studies. Highlights: We investigated neuroimaging and cognitive biomarkers in 3036 cognitively unimpaired (CU) participants. Medial temporal lobe (MTL) tau and longitudinal MTL atrophy best separate amyloid beta positive (A+) CU from amyloid beta negative (A–) CU. A– tau positive (T+) CU had a significantly faster neurodegeneration rate compared to A–T– CU. MTL tau correlated with structural magnetic resonance imaging (MRI) and cognition regardless of amyloid beta status. Combined baseline MTL tau, MRI, and cognition best predict Alzheimer's disease progression.
- Open Access
- 9 January 2025
- Published by Springer Nature in Neuroinformatics
- Vol. 23 (1) , 1-15
Automated Lesion and Feature Extraction Pipeline for Brain MRIs with Interpretability
This paper introduces the Automated Lesion and Feature Extraction (ALFE) pipeline, an open-source, Python-based pipeline that consumes MR images of the brain and produces anatomical segmentations, lesion segmentations, and human-interpretable imaging features describing the lesions in the brain. ALFE pipeline is modeled after the neuroradiology workflow and generates features that can be used by physicians for quantitative analysis of clinical brain MRIs and for machine learning applications. The pipeline uses a decoupled design which allows the user to customize the image processing, image registrations, and AI segmentation tools without the need to change the business logic of the pipeline. In this manuscript, we give an overview of ALFE, present the main aspects of ALFE pipeline design philosophy, and present case studies.
- 9 January 2025
- Published by Springer Nature in Neuroinformatics
- Vol. 23 (1) , 1-15
Open AccessAutomated Lesion and Feature Extraction Pipeline for Brain MRIs with Interpretability
This paper introduces the Automated Lesion and Feature Extraction (ALFE) pipeline, an open-source, Python-based pipeline that consumes MR images of the brain and produces anatomical segmentations, lesion segmentations, and human-interpretable imaging features describing the lesions in the brain. ALFE pipeline is modeled after the neuroradiology workflow and generates features that can be used by physicians for quantitative analysis of clinical brain MRIs and for machine learning applications. The pipeline uses a decoupled design which allows the user to customize the image processing, image registrations, and AI segmentation tools without the need to change the business logic of the pipeline. In this manuscript, we give an overview of ALFE, present the main aspects of ALFE pipeline design philosophy, and present case studies.
- Open Access
- 12 January 2024
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 16 (1) , 1
Correction: Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease
- 12 January 2024
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 16 (1) , 1
Open AccessCorrection: Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Medial temporal lobe gray matter microstructure alterations provide improved sensitivity to detect neurodegeneration associated with Alzheimer’s disease biomarkers
Background: Despite the strengths conventional structural imaging measures to detect atrophy, cross‐sectional relationships between neurodegeneration and Alzheimer’s disease (AD) biomarkers in early stages is limited. Neurite orientation dispersion and density imaging (NODDI) measures microstructural alterations that are unique from conventional structural metrics. Alterations in microstructure have been detected in individuals with AD compared to cognitively normal individuals, but there is sparse data regarding the relationship between these metrics and AD biomarkers. Here we sought to characterize how NODDI metrics in the medial temporal lobe (MTL) are associated with plasma AD biomarkers.Method: One‐hundred and sixty‐seven cognitively normal (CN) individuals, 47 individuals with mild cognitive impairment, and 16 individuals with AD underwent diffusion and T1w imaging. T1w images were segmented using the ASHS‐T1 protocol to form anterior and posterior MTL ROIs. Multi‐shell DTI data were collected in 113 non‐collinear directions with 1.5mm isotropic voxels, were pre‐processed using a custom pipeline, and fit with voxel‐wise NODDI models. ANTs was used to linearly register NODDI and T1w images to allow transformation of MTL ROIs to diffusion space. Stepwise‐regression models examined relationships between anterior and posterior MTL NODDI metrics with plasma biomarkers in CN and impaired (MCI/AD) groups after accounting for MTL volume.Result: NODDI metrics of intracellular volume fraction (icVf) and orientation dispersion index (ODI) were decreased, and isometric volume fraction (isoVf) was increased in cognitively impaired compared to CN. Amyloid positivity was associated with decreased ODI and increased isoVf in cognitively impaired individuals. While posterior MTL volume predicted plasma p‐Tau‐181, inclusion of NODDI metrics subsumed this effect (F‐change>7.54, p12.68, p<.001). Anterior MTL icVf predicted both pTau‐181 and GFAP.Conclusion: Microstructural alterations measured by NODDI appear more closely linked to AD‐related molecular measures and, thus, may provide a more sensitive cross‐sectional measure of neurodegeneration of the MTL compared to conventional macrostructural metrics.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Open AccessMedial temporal lobe gray matter microstructure alterations provide improved sensitivity to detect neurodegeneration associated with Alzheimer’s disease biomarkers
Background: Despite the strengths conventional structural imaging measures to detect atrophy, cross‐sectional relationships between neurodegeneration and Alzheimer’s disease (AD) biomarkers in early stages is limited. Neurite orientation dispersion and density imaging (NODDI) measures microstructural alterations that are unique from conventional structural metrics. Alterations in microstructure have been detected in individuals with AD compared to cognitively normal individuals, but there is sparse data regarding the relationship between these metrics and AD biomarkers. Here we sought to characterize how NODDI metrics in the medial temporal lobe (MTL) are associated with plasma AD biomarkers.Method: One‐hundred and sixty‐seven cognitively normal (CN) individuals, 47 individuals with mild cognitive impairment, and 16 individuals with AD underwent diffusion and T1w imaging. T1w images were segmented using the ASHS‐T1 protocol to form anterior and posterior MTL ROIs. Multi‐shell DTI data were collected in 113 non‐collinear directions with 1.5mm isotropic voxels, were pre‐processed using a custom pipeline, and fit with voxel‐wise NODDI models. ANTs was used to linearly register NODDI and T1w images to allow transformation of MTL ROIs to diffusion space. Stepwise‐regression models examined relationships between anterior and posterior MTL NODDI metrics with plasma biomarkers in CN and impaired (MCI/AD) groups after accounting for MTL volume.Result: NODDI metrics of intracellular volume fraction (icVf) and orientation dispersion index (ODI) were decreased, and isometric volume fraction (isoVf) was increased in cognitively impaired compared to CN. Amyloid positivity was associated with decreased ODI and increased isoVf in cognitively impaired individuals. While posterior MTL volume predicted plasma p‐Tau‐181, inclusion of NODDI metrics subsumed this effect (F‐change>7.54, p12.68, p<.001). Anterior MTL icVf predicted both pTau‐181 and GFAP.Conclusion: Microstructural alterations measured by NODDI appear more closely linked to AD‐related molecular measures and, thus, may provide a more sensitive cross‐sectional measure of neurodegeneration of the MTL compared to conventional macrostructural metrics.
- Open Access
- 24 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S10)
Medial temporal lobe gray matter microstructure alterations provide improved sensitivity to detect neurodegeneration associated with Alzheimer’s disease biomarkers
Background: Despite the strengths conventional structural imaging measures to detect atrophy, cross‐sectional relationships between neurodegeneration and Alzheimer’s disease (AD) biomarkers in early stages is limited. Neurite orientation dispersion and density imaging (NODDI) measures microstructural alterations that are unique from conventional structural metrics. Alterations in microstructure have been detected in individuals with AD compared to cognitively normal individuals, but there is sparse data regarding the relationship between these metrics and AD biomarkers. Here we sought to characterize how NODDI metrics in the medial temporal lobe (MTL) are associated with plasma AD biomarkers.Method: One‐hundred and sixty‐seven cognitively normal (CN) individuals, 47 individuals with mild cognitive impairment, and 16 individuals with AD underwent diffusion and T1w imaging. T1w images were segmented using the ASHS‐T1 protocol to form anterior and posterior MTL ROIs. Multi‐shell DTI data were collected in 113 non‐collinear directions with 1.5mm isotropic voxels, were pre‐processed using a custom pipeline, and fit with voxel‐wise NODDI models. ANTs was used to linearly register NODDI and T1w images to allow transformation of MTL ROIs to diffusion space. Stepwise‐regression models examined relationships between anterior and posterior MTL NODDI metrics with plasma biomarkers in CN and impaired (MCI/AD) groups after accounting for MTL volume.Result: NODDI metrics of intracellular volume fraction (icVf) and orientation dispersion index (ODI) were decreased, and isometric volume fraction (isoVf) was increased in cognitively impaired compared to CN. Amyloid positivity was associated with decreased ODI and increased isoVf in cognitively impaired individuals. While posterior MTL volume predicted plasma p‐Tau‐181, inclusion of NODDI metrics subsumed this effect (F‐change>7.54, p12.68, p<.001). Anterior MTL icVf predicted both pTau‐181 and GFAP.Conclusion: Microstructural alterations measured by NODDI appear more closely linked to AD‐related molecular measures and, thus, may provide a more sensitive cross‐sectional measure of neurodegeneration of the MTL compared to conventional macrostructural metrics.
- 24 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S10)
Open AccessMedial temporal lobe gray matter microstructure alterations provide improved sensitivity to detect neurodegeneration associated with Alzheimer’s disease biomarkers
Background: Despite the strengths conventional structural imaging measures to detect atrophy, cross‐sectional relationships between neurodegeneration and Alzheimer’s disease (AD) biomarkers in early stages is limited. Neurite orientation dispersion and density imaging (NODDI) measures microstructural alterations that are unique from conventional structural metrics. Alterations in microstructure have been detected in individuals with AD compared to cognitively normal individuals, but there is sparse data regarding the relationship between these metrics and AD biomarkers. Here we sought to characterize how NODDI metrics in the medial temporal lobe (MTL) are associated with plasma AD biomarkers.Method: One‐hundred and sixty‐seven cognitively normal (CN) individuals, 47 individuals with mild cognitive impairment, and 16 individuals with AD underwent diffusion and T1w imaging. T1w images were segmented using the ASHS‐T1 protocol to form anterior and posterior MTL ROIs. Multi‐shell DTI data were collected in 113 non‐collinear directions with 1.5mm isotropic voxels, were pre‐processed using a custom pipeline, and fit with voxel‐wise NODDI models. ANTs was used to linearly register NODDI and T1w images to allow transformation of MTL ROIs to diffusion space. Stepwise‐regression models examined relationships between anterior and posterior MTL NODDI metrics with plasma biomarkers in CN and impaired (MCI/AD) groups after accounting for MTL volume.Result: NODDI metrics of intracellular volume fraction (icVf) and orientation dispersion index (ODI) were decreased, and isometric volume fraction (isoVf) was increased in cognitively impaired compared to CN. Amyloid positivity was associated with decreased ODI and increased isoVf in cognitively impaired individuals. While posterior MTL volume predicted plasma p‐Tau‐181, inclusion of NODDI metrics subsumed this effect (F‐change>7.54, p12.68, p<.001). Anterior MTL icVf predicted both pTau‐181 and GFAP.Conclusion: Microstructural alterations measured by NODDI appear more closely linked to AD‐related molecular measures and, thus, may provide a more sensitive cross‐sectional measure of neurodegeneration of the MTL compared to conventional macrostructural metrics.
- Open Access
- 11 April 2023
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 15 (1) , 1-14
Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease
Background: Crucial to the success of clinical trials targeting early Alzheimer’s disease (AD) is recruiting participants who are more likely to progress over the course of the trials. We hypothesize that a combination of plasma and structural MRI biomarkers, which are less costly and non-invasive, is predictive of longitudinal progression measured by atrophy and cognitive decline in early AD, providing a practical alternative to PET or cerebrospinal fluid biomarkers. Methods: Longitudinal T1-weighted MRI, cognitive (memory-related test scores and clinical dementia rating scale), and plasma measurements of 245 cognitively normal (CN) and 361 mild cognitive impairment (MCI) patients from ADNI were included. Subjects were further divided into β-amyloid positive/negative (Aβ+/Aβ−)] subgroups. Baseline plasma (p-tau181 and neurofilament light chain) and MRI-based structural medial temporal lobe subregional measurements and their association with longitudinal measures of atrophy and cognitive decline were tested using stepwise linear mixed effect modeling in CN and MCI, as well as separately in the Aβ+/Aβ− subgroups. Receiver operating characteristic (ROC) analyses were performed to investigate the discriminative power of each model in separating fast and slow progressors (first and last terciles) of each longitudinal measurement. Results: A total of 245 CN (35.0% Aβ+) and 361 MCI (53.2% Aβ+) participants were included. In the CN and MCI groups, both baseline plasma and structural MRI biomarkers were included in most models. These relationships were maintained when limited to the Aβ+ and Aβ− subgroups, including Aβ− CN (normal aging). ROC analyses demonstrated reliable discriminative power in identifying fast from slow progressors in MCI [area under the curve (AUC): 0.78–0.93] and more modestly in CN (0.65–0.73). Conclusions: The present data support the notion that plasma and MRI biomarkers, which are relatively easy to obtain, provide a prediction for the rate of future cognitive and neurodegenerative progression that may be particularly useful in clinical trial stratification and prognosis. Additionally, the effect in Aβ− CN indicates the potential use of these biomarkers in predicting a normal age-related decline.
- 11 April 2023
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 15 (1) , 1-14
Open AccessBaseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease
Background: Crucial to the success of clinical trials targeting early Alzheimer’s disease (AD) is recruiting participants who are more likely to progress over the course of the trials. We hypothesize that a combination of plasma and structural MRI biomarkers, which are less costly and non-invasive, is predictive of longitudinal progression measured by atrophy and cognitive decline in early AD, providing a practical alternative to PET or cerebrospinal fluid biomarkers. Methods: Longitudinal T1-weighted MRI, cognitive (memory-related test scores and clinical dementia rating scale), and plasma measurements of 245 cognitively normal (CN) and 361 mild cognitive impairment (MCI) patients from ADNI were included. Subjects were further divided into β-amyloid positive/negative (Aβ+/Aβ−)] subgroups. Baseline plasma (p-tau181 and neurofilament light chain) and MRI-based structural medial temporal lobe subregional measurements and their association with longitudinal measures of atrophy and cognitive decline were tested using stepwise linear mixed effect modeling in CN and MCI, as well as separately in the Aβ+/Aβ− subgroups. Receiver operating characteristic (ROC) analyses were performed to investigate the discriminative power of each model in separating fast and slow progressors (first and last terciles) of each longitudinal measurement. Results: A total of 245 CN (35.0% Aβ+) and 361 MCI (53.2% Aβ+) participants were included. In the CN and MCI groups, both baseline plasma and structural MRI biomarkers were included in most models. These relationships were maintained when limited to the Aβ+ and Aβ− subgroups, including Aβ− CN (normal aging). ROC analyses demonstrated reliable discriminative power in identifying fast from slow progressors in MCI [area under the curve (AUC): 0.78–0.93] and more modestly in CN (0.65–0.73). Conclusions: The present data support the notion that plasma and MRI biomarkers, which are relatively easy to obtain, provide a prediction for the rate of future cognitive and neurodegenerative progression that may be particularly useful in clinical trial stratification and prognosis. Additionally, the effect in Aβ− CN indicates the potential use of these biomarkers in predicting a normal age-related decline.